Distribution of the Homologous Recombination-related (HRR) Genesmutationsand HRD in Breast Cancer

Plain-language summary

This study examines the distribution of homologous recombination-related (HRR) gene mutations and homologous recombination deficiency (HRD) in breast cancer. It enrolls women aged 18-70 with operable, HER2-low breast cancer. It is a study without a phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Intervention

Standard Management

Start date

8/7/2022

Estimated completion

5/31/2027

Countries

China

Related genes

Locations

• Guangzhou, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. Female patients aged 18-70 years with pathologically confirmed HER2-low breast cancer (defined as IHC 2+/ISH- or IHC 1+ per ASCO/CAP guidelines);
2. ECOG performance status of 0 or 1;
3. Treatment-naïve operable primary breast cancer with completed homologous recombination deficiency (HRD) assessment;

5）Absence of distant metastasis; 6）Availability of adequate tumor tissue and blood samples for biomarker analysis.

Exclusion Criteria:

1. Recurrent or inoperable locally advanced breast cancer;
2. Bilateral breast cancer;
3. History of other malignant tumors within the past 5 years;
4. Incomplete clinical or pathological data.